Ebola Virus Vaccine Developer CANSINO Successfully Got Listed In HK

0
203

On 28thof March, CanSino Biologics Inc. (康希諾生物股份公司) (“CanSinoBIO”or the “Company”; stock code: 6185), formally loaded on the Main Board of The Stock Exchange of Hong Kong Limited (“SEHK”). The price for each H share is between 21 HK dollar and 22 HK dollar, making the total raised fund up to HK$1,259 million after selling all shares.

Morgan Stanley Asia Limited and CLSA Capital Markets Limited are the Joint Sponsors. Morgan Stanley Asia Limited, CLSA Limited and China International Capital Corporation Hong Kong Securities Limited are the Joint Global Coordinators. Morgan Stanley Asia Limited, Morgan Stanley & Co. International plc, CLSA Limited, China International Capital Corporation Hong Kong Securities Limited, ICBC International Capital Limited and CMB International Capital Limited are the Joint Bookrunners. Morgan Stanley Asia Limited, Morgan Stanley & Co. International plc, CLSA Limited, China International Capital Corporation Hong Kong Securities Limited, ICBC International Securities Limited and CMB International Capital Limited are the Joint Lead Managers.

Found in 2009, CanSino is famous for having developed the human using vaccine Ad5-EBOV, the first approved Ebola virus vaccine in China for emergency use and national stockpile. The company’s main focus is to develop pipeline for vaccine products that can help prevent a series of diseases as pneumonia, tuberculosis, Ebola virus disease, meningitis, white blood, cervical cancer and so on. Based on its innovative technologies including adenovirus- based viral vector vaccine technology, conjugation technology, protein structure design and recombinant technology and formulation technology, CanSino is making continuous efforts to bring its goal come true.

LEAVE A REPLY

Please enter your comment!
Please enter your name here